197 related articles for article (PubMed ID: 26253259)
1. Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.
Kim DW; Kim HJ; Kim KW; Byun JH; Kim SY; Song KB; Ramaiya NH; Tirumani SH; Hong SM
Eur Radiol; 2016 May; 26(5):1320-9. PubMed ID: 26253259
[TBL] [Abstract][Full Text] [Related]
2. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour.
Kim DW; Kim HJ; Kim KW; Byun JH; Song KB; Kim JH; Hong SM
Eur Radiol; 2015 May; 25(5):1375-83. PubMed ID: 25465713
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
[TBL] [Abstract][Full Text] [Related]
5. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT in pancreatic neuroendocrine neoplasms.
Park HJ; Kim HJ; Kim JH; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
Eur Radiol; 2023 Apr; 33(4):2713-2724. PubMed ID: 36378252
[TBL] [Abstract][Full Text] [Related]
7. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation.
Kawamura Y; Ikeda K; Seko Y; Hosaka T; Kobayashi M; Saitoh S; Kumada H
AJR Am J Roentgenol; 2011 Oct; 197(4):W665-73. PubMed ID: 21940538
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.
Chen HY; Pan Y; Chen JY; Liu LL; Yang YB; Li K; Yu RS; Shao GL
Eur Radiol; 2022 Dec; 32(12):8317-8325. PubMed ID: 35759016
[TBL] [Abstract][Full Text] [Related]
10. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
11. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
12. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings.
Lee KW; Lee Y; Oh SW; Jin KN; Goo JM
Eur J Radiol; 2015 Nov; 84(11):2332-8. PubMed ID: 26279139
[TBL] [Abstract][Full Text] [Related]
13. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
Li JK; Wang M; Yuan J; Song ZG
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
[No Abstract] [Full Text] [Related]
14. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
Han S; Kim JH; Yoo J; Jang S
Eur Radiol; 2022 Apr; 32(4):2506-2517. PubMed ID: 34647178
[TBL] [Abstract][Full Text] [Related]
15. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
16. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection.
Arai T; Kobayashi A; Fujinaga Y; Yokoyama T; Shimizu A; Motoyama H; Kitagawa N; Notake T; Shirota T; Fukushima K; Masuo H; Kadoya M; Miyagawa S
Pancreatology; 2016; 16(3):397-402. PubMed ID: 26850565
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.
Ren S; Chen X; Wang Z; Zhao R; Wang J; Cui W; Wang Z
PLoS One; 2019; 14(2):e0211566. PubMed ID: 30707733
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens.
Tatsumoto S; Kodama Y; Sakurai Y; Shinohara T; Katanuma A; Maguchi H
Abdom Imaging; 2013 Apr; 38(2):358-66. PubMed ID: 22945422
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
